Marianne Schultzberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6374067/publications.pdf

Version: 2024-02-01

104 papers 7,166 citations

43 h-index 83 g-index

105 all docs

105
docs citations

105 times ranked 5820 citing authors

#	Article	IF	CITATIONS
1	Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer's Disease. Cellular and Molecular Neurobiology, 2023, 43, 797-811.	3.3	19
2	Intranasal delivery of pro-resolving lipid mediators rescues memory and gamma oscillation impairment in AppNL-G-F/NL-G-F mice. Communications Biology, 2022, 5, 245.	4.4	25
3	Maresin 1 attenuates proâ€inflammatory activation induced by βâ€amyloid and stimulates its uptake. Journal of Cellular and Molecular Medicine, 2021, 25, 434-447.	3.6	16
4	Reduced Levels of Plasma Lipoxin A4 Are Associated with Post-Stroke Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 79, 607-613.	2.6	10
5	Role of polyunsaturated fatty acids in ischemic stroke – A perspective of specialized pro-resolving mediators. Clinical Nutrition, 2021, 40, 2974-2987.	5.0	15
6	Cerebrospinal Fluid Inflammatory Markers in Alzheimer's Disease: Influence of Comorbidities. Current Alzheimer Research, 2021, 18, 157-170.	1.4	3
7	Age-related changes in brain phospholipids and bioactive lipids in the APP knock-in mouse model of Alzheimer's disease. Acta Neuropathologica Communications, 2021, 9, 116.	5.2	28
8	Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trialâ€"The OmegAD Study. Journal of Alzheimer's Disease, 2021, 83, 1291-1301.	2.6	10
9	Receptors for proâ€resolving mediators are increased in Alzheimer's disease brain. Brain Pathology, 2020, 30, 614-640.	4.1	41
10	Chronic Airway Allergy Induces Pro-Inflammatory Responses in the Brain of Wildtype Mice but Not 3xTgAD Mice. Neuroscience, 2020, 448, 14-27.	2.3	0
11	RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome. Glia, 2020, 68, 1347-1360.	4.9	24
12	Can inflammation be resolved in Alzheimer's disease?. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879110.	3.5	42
13	DHA-rich n–3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study. American Journal of Clinical Nutrition, 2017, 106, 1157-1165.	4.7	46
14	Inflammation and its resolution – studies in Alzheimer's disease. Neurobiology of Aging, 2016, 39, S17.	3.1	0
15	Detrimental effects of a high fat/high cholesterol diet on memory and hippocampal markers in aged rats. Behavioural Brain Research, 2016, 312, 294-304.	2.2	70
16	Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase AÎ ² 42 Phagocytosis. Molecular Neurobiology, 2016, 53, 2733-2749.	4.0	152
17	Plasma Fatty Acid Profiles in Relation toÂCognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 FattyÂAcid Supplementation: The OmegADÂStudy. Journal of Alzheimer's Disease, 2015, 48, 805-812.	2.6	82
18	Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 495-505.	2.6	9

#	Article	IF	Citations
19	Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research, 2015, 56, 674-681.	4.2	63
20	Resolution of inflammation is altered in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 40.	0.8	208
21	Insufficient Resolution Response in the Hippocampus of a Senescence-Accelerated Mouse Model — SAMP8. Journal of Molecular Neuroscience, 2015, 55, 396-405.	2.3	19
22	Neuropsychiatric symptoms in dementia—A role for neuroinflammation?. Brain Research Bulletin, 2014, 108, 88-93.	3.0	44
23	Differential Regulation of Resolution in Inflammation induced by Amyloid-Î ² 42 and Lipopolysaccharides in Human Microglia. Journal of Alzheimer's Disease, 2014, 43, 1237-1250.	2.6	37
24	Effects of Supplementation with Omega-3 Fatty Acids on Oxidative Stress and Inflammation in Patients with Alzheimer's Disease: The OmegAD Study. Journal of Alzheimer's Disease, 2014, 42, 823-831.	2.6	61
25	Analysis of Matrix Metallo-Proteases and the Plasminogen System in Mild Cognitive Impairment and Alzheimer's Disease Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2014, 40, 667-678.	2.6	55
26	Chronic airway-induced allergy in mice modifies gene expression in the brain toward insulin resistance and inflammatory responses. Journal of Neuroinflammation, 2013, 10, 99.	7.2	19
27	Interplay between human microglia and neural stem/progenitor cells in an allogeneic coâ€culture model. Journal of Cellular and Molecular Medicine, 2013, 17, 1434-1443.	3.6	39
28	Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid-Î ² 42 by Human Microglia and Decrease Inflammatory Markers. Journal of Alzheimer's Disease, 2013, 35, 697-713.	2.6	190
29	Allergy influences the inflammatory status of the brain and enhances tauâ€phosphorylation. Journal of Cellular and Molecular Medicine, 2012, 16, 2401-2412.	3.6	31
30	Cytokines and memory across the mature life span of women. Scandinavian Journal of Psychology, 2011, 52, 229-235.	1.5	22
31	Morphological and behavioral changes induced by transgenic overexpression of interleukinâ€1ra in the brain. Journal of Neuroscience Research, 2011, 89, 142-152.	2.9	10
32	Effects of Immunomodulatory Substances on Phagocytosis of A by Human Microglia. International Journal of Alzheimer's Disease, 2010, 2010, 1-18.	2.0	17
33	Reduced prostaglandin F2α release from blood mononuclear leukocytes after oral supplementation of ω3 fatty acids: the OmegAD study. Journal of Lipid Research, 2010, 51, 1179-1185.	4.2	43
34	Chemical signaling in the nervous system in health and disease: Nils-Ãke Hillarp's legacy. Progress in Neurobiology, 2010, 90, 71-74.	5.7	0
35	Connection between inflammatory processes and transmittor function—Modulatory effects of interleukin-1. Progress in Neurobiology, 2010, 90, 256-262.	5.7	32
36	Effects of Omega-3 Fatty Acids on Inflammatory Markers in Cerebrospinal Fluid and Plasma in Alzheimer's Disease: The OmegAD Study. Dementia and Geriatric Cognitive Disorders, 2009, 27, 481-490.	1.5	82

#	Article	IF	CITATIONS
37	Impaired long term memory consolidation in transgenic mice overexpressing the human soluble form of IL-1ra in the brain. Journal of Neuroimmunology, 2009, 208, 46-53.	2.3	55
38	Activityâ€Regulated Cytoskeletonâ€Associated Protein in Rodent Brain is Downâ€Regulated by High Fat Diet <i>in vivo</i> and by 27â€Hydroxycholesterol <i>in vitro</i> . Brain Pathology, 2009, 19, 69-80.	4.1	78
39	Blood-brain barrier alterations in ageing and dementia. Journal of the Neurological Sciences, 2009, 283, 99-106.	0.6	197
40	Blunted neurogenesis and gliosis due to transgenic overexpression of human soluble ILâ€1ra in the mouse. European Journal of Neuroscience, 2008, 27, 549-558.	2.6	50
41	Inflammation in the nervous system — Physiological and pathophysiological aspects. Physiology and Behavior, 2007, 92, 121-128.	2.1	54
42	Interleukinâ€1 System in CNS Stress. Annals of the New York Academy of Sciences, 2007, 1113, 173-177.	3.8	105
43	\hat{l}_{\pm} -MSH Rescues Neurons from Excitotoxic Cell Death. Journal of Molecular Neuroscience, 2007, 33, 239-251.	2.3	37
44	The influence of kainic acid on core temperature and cytokine levels in the brain. Cytokine, 2006, 35, 77-87.	3.2	18
45	α-Melanocyte-stimulating hormone is neuroprotective in rat global cerebral ischemia. Neuropeptides, 2006, 40, 65-75.	2.2	64
46	??-MSH decreases core and brain temperature during global cerebral ischemia in rats. NeuroReport, 2005, 16, 69-72.	1.2	14
47	Î ² -Amyloid Protein Structure Determines the Nature of Cytokine Release From Rat Microglia. Journal of Molecular Neuroscience, 2005, 27, 001-012.	2.3	68
48	Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. Journal of Neuroimmunology, 2005, 166, 132-143.	2.3	116
49	Cytokine production by a human microglial cell line: Effects of ßamyloid and α-melanocyte-stimulating hormone. Neurotoxicity Research, 2005, 8, 267-276.	2.7	41
50	Effects of statins on microglia. Journal of Neuroscience Research, 2005, 82, 10-19.	2.9	45
51	Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease. Neurochemistry International, 2005, 46, 551-557.	3.8	49
52	Transgenic overexpression of interleukin-1 receptor antagonist in the CNS influences behaviour, serum corticosterone and brain monoamines. Brain, Behavior, and Immunity, 2005, 19, 223-234.	4.1	28
53	High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Letters, 2005, 579, 6411-6416.	2.8	62
54	Neuronal expression of caspase-1 immunoreactivity in the rat central nervous system. Journal of Neuroimmunology, 2004, 146, 99-113.	2.3	12

#	Article	IF	CITATIONS
55	Effects of chronic overexpression of interleukin-1 receptor antagonist in a model of permanent focal cerebral ischemia in mouse. Acta Neuropathologica, 2004, 108, 69-80.	7.7	15
56	Increased sensitivity to N-methyl-d-aspartate receptor-induced excitotoxicity in cerebellar granule cells from interleukin-1 receptor type l-deficient mice. Journal of Neuroimmunology, 2002, 133, 108-115.	2.3	7
57	Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neuroscience Letters, 2001, 301, 54-58.	2.1	41
58	Expression and Distribution of Tartrate-resistant Purple Acid Phosphatase in the Rat Nervous System. Journal of Histochemistry and Cytochemistry, 2001, 49, 379-396.	2.5	42
59	Increased expression of mRNA encoding interleukin-1? and caspase-1, and the secreted isoform of interleukin-1 receptor antagonist in the rat brain following systemic kainic acid administration. Journal of Neuroscience Research, 2000, 60, 266-279.	2.9	67
60	EXPRESSION OF INTERLEUKIN $1\hat{1}$ AND $\hat{1}$, AND INTERLEUKIN 1 RECEPTOR ANTAGONIST mRNA IN THE RAT CENTRANERVOUS SYSTEM AFTER PERIPHERAL ADMINISTRATION OF LIPOPOLYSACCHARIDES. Cytokine, 2000, 12, 423-431.	AL 3.2	88
61	Inhibition of kainic acid induced expression of interleukin- $\hat{\Pi}^2$ and interleukin-1 receptor antagonist mRNA in the rat brain by NMDA receptor antagonists. Molecular Brain Research, 2000, 85, 103-113.	2.3	31
62	Provocation With Stress and Electricity of Patients With ???Sensitivity to Electricity???. Journal of Occupational and Environmental Medicine, 2000, 42, 512-516.	1.7	35
63	Acute-phase responses in transgenic mice with CNS overexpression of IL-1 receptor antagonist. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 276, R644-R651.	1.8	27
64	Expression of presenilin 1 mRNA in rat peripheral organs and brain. The Histochemical Journal, 1999, 31, 515-523.	0.6	10
65	Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Research, 1999, 826, 112-116.	2.2	78
66	Neurokinin A in rat adjuvant arthritis. Effect of capsaicin treatment. NeuroReport, 1999, 10, 3307-3313.	1.2	1
67	Effects of Peripheral Administration of LPS on the Expression of Immunoreactive Interleukin- $1\hat{l}_{\pm}$, \hat{l}_{2} , and Receptor Antagonist in Rat Brain. Annals of the New York Academy of Sciences, 1998, 840, 128-138.	3.8	57
68	Kainic acid induced expression of interleukin-1 receptor antagonist mRNA in the rat brain. Molecular Brain Research, 1998, 58, 195-208.	2.3	51
69	Peptidergic innervation of the internal anal sphincter in Hirschsprung's disease. Pediatric Surgery International, 1996, 11, 33-40.	1.4	1
70	Regionally specific induction of ICE mRNA and enzyme activity in the rat brain and adrenal gland by LPS. Brain Research, 1996, 712, 153-158.	2.2	32
71	Proinflammatory cytokines and their corresponding receptor proteins in eccrine sweat glands in normal and cutaneous leishmaniasis human skin. An immunohistochemical study. Experimental Dermatology, 1996, 5, 230-235.	2.9	21
72	Interleukin (IL)- $1\hat{1}$ ±- and $-1\hat{1}^2$ -, IL-6-, and Tumor Necrosis Factor- $\hat{1}$ ±-like Immunoreactivities in Human Common and Dysplastic Nevocellular Nevi and Malignant Melanoma. American Journal of Dermatopathology, 1995, 17, 222-229.	0.6	16

#	Article	IF	CITATIONS
73	Increased levels of substance p and calcitonin gene-related peptide in rat adjuvant arthritis: combined immunohistochemical and radioimmunoassay analysis. Arthritis and Rheumatism, 1995, 38, 699-709.	6.7	89
74	Induction of Interleukin- $\hat{1}^2$ mRNA and Enkephalin mRNA in the Rat Adrenal Gland by Lipopolysaccharides Studied by in situ Hybridization Histochemistry (Part 1 of 2). NeuroImmunoModulation, 1995, 2, 61-67.	1.8	25
75	Interleukin-1 Receptor Antagonist Protein and mRNA in the Rat Adrenal Gland. Journal of Interferon and Cytokine Research, 1995, 15, 721-729.	1.2	22
76	Effects of surgical denervation on substance P and calcitonin gene-related peptide in adjuvant arthritis. Peptides, 1995, 16, 569-579.	2.4	20
77	Capsaicin effects on substance P and CGRP in rat adjuvant arthritis. Regulatory Peptides, 1995, 55, 85-102.	1.9	56
78	Cytokines in neuronal cell types. Neurochemistry International, 1993, 22, 435-444.	3.8	103
79	Immunohistochemical and behaviour pharmacological analysis of rats inoculated intranasally with vesicular stomatitis virus. Journal of Chemical Neuroanatomy, 1993, 6, 7-18.	2.1	13
80	Expression of tyrosine hydroxylase in cerebellar Purkinje neurons of the mutant tottering and leaner mouse. Molecular Brain Research, 1992, 15, 227-240.	2.3	79
81	Cytokine Regulation of Neuronal Survival. Journal of Neurochemistry, 1992, 58, 454-460.	3.9	204
82	Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106–01, ROS 17/2.8,) Tj ETC	Qq <u>Q</u> ,Q 0 rg	BT /Overlock 129
82	Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106–01, ROS 17/2.8,) Tj ETG Location of interleukin-1 in the nervous system. , 1992, , 1-11.	QqQ Q 0 rg	BT/Qverlock
		2.0	12)
83	Location of interleukin-1 in the nervous system. , 1992, , 1-11. Dopamine- and adenosine-3′,5′-monophosphate (cAMP)-regulated phosphoprotein of 32 kDa (DARRP-32) i the adrenal gland: immunohistochemical localization. Journal of the Autonomic Nervous System, 1991,	n	2
83	Location of interleukin-1 in the nervous system. , 1992, , 1-11. Dopamine- and adenosine-3′,5′-monophosphate (cAMP)-regulated phosphoprotein of 32 kDa (DARRP-32) it the adrenal gland: immunohistochemical localization. Journal of the Autonomic Nervous System, 1991, 36, 75-84. NMDA-Receptor Antagonist Prevents Measles Virus-induced Neurodegeneration. European Journal of	n 1.9	2
83 84 85	Location of interleukin-1 in the nervous system. , 1992, , 1-11. Dopamine- and adenosine-3′,5′-monophosphate (cAMP)-regulated phosphoprotein of 32 kDa (DARRP-32) it the adrenal gland: immunohistochemical localization. Journal of the Autonomic Nervous System, 1991, 36, 75-84. NMDA-Receptor Antagonist Prevents Measles Virus-induced Neurodegeneration. European Journal of Neuroscience, 1991, 3, 66-71. Chapter 2 Genetically altered and defined cell lines for transplantation in animal models of	n 1.9 2.6	2 7 34
83 84 85 86	Location of interleukin-1 in the nervous system. , 1992, , 1-11. Dopamine- and adenosine-3′,5′-monophosphate (cAMP)-regulated phosphoprotein of 32 kDa (DARRP-32) is the adrenal gland: immunohistochemical localization. Journal of the Autonomic Nervous System, 1991, 36, 75-84. NMDA-Receptor Antagonist Prevents Measles Virus-induced Neurodegeneration. European Journal of Neuroscience, 1991, 3, 66-71. Chapter 2 Genetically altered and defined cell lines for transplantation in animal models of Parkinson's disease. Progress in Brain Research, 1990, 82, 11-21.	n 1.9 2.6	2 7 34 20
83 84 85 86	Location of interleukin-1 in the nervous system. , 1992, , 1-11. Dopamine- and adenosine-3′,5′-monophosphate (cAMP)-regulated phosphoprotein of 32 kDa (DARRP-32) is the adrenal gland: immunohistochemical localization. Journal of the Autonomic Nervous System, 1991, 36, 75-84. NMDA-Receptor Antagonist Prevents Measles Virus-induced Neurodegeneration. European Journal of Neuroscience, 1991, 3, 66-71. Chapter 2 Genetically altered and defined cell lines for transplantation in animal models of Parkinson's disease. Progress in Brain Research, 1990, 82, 11-21. Interleukin-1 in the Noradrenergic Chromaffin Cells in the Rat Adrenal Medulla. Annals of the New York Academy of Sciences, 1990, 594, 207-213. Nerve fibre studies in skin biopsies in peripheral neuropathies. I. Immunohistochemical analysis of	n 1.9 2.6 1.4	2 7 34 20

#	Article	IF	CITATIONS
91	The mismatch problem in receptor autoradiography and the coexistence of multiple messengers. Trends in Neurosciences, 1986, 9, 109-110.	8.6	28
92	Chapter 4 Coexistence of neuronal messengers — an overview. Progress in Brain Research, 1986, 68, 33-70.	1.4	180
93	Ephemeral existence of a single catecholamine synthetic enzyme in the olfactory placode and the spinal cord of the embryonic rat. International Journal of Developmental Neuroscience, 1985, 3, 597-608.	1.6	13
94	Differential ontogeny of three putative catecholamine cell types in the postnatal rat retina. Developmental Brain Research, 1985, 22, 187-196.	1.7	27
95	Capsaicin depletes CCK-like immunoreactivity detected by immunohistochemistry, but not that measured by radioimmunoassay in rat dorsal spinal cord. Brain Research, 1982, 235, 198-204.	2.2	107
96	COEXISTENCE OF CLASSICAL TRANSMITTERS AND PEPTIDES IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS. British Medical Bulletin, 1982, 38, 309-314.	6.9	45
97	Distribution of Substance P in Brain and Periphery and its Possible Role as a Coâ€Transmitter. Novartis Foundation Symposium, 1982, , 84-106.	1.1	30
98	Immunohistochemical evidence for a local VIPâ€ergic neuron system in the adrenal gland of the rat. Acta Physiologica Scandinavica, 1981, 113, 575-576.	2.2	111
99	Peptidergic neurones. Nature, 1980, 284, 515-521.	27.8	1,682
100	Substance P-like immunoreactivity in cultured spinal ganglia from chick embryos. Journal of Neurocytology, 1978, 7, 107-117.	1.5	14
101	Enkephalinâ€ike immunoreactivity in nerve terminals in sympathetic ganglia and adrenal medulla and in adrenal medullary gland cells. Acta Physiologica Scandinavica, 1978, 103, 475-477.	2.2	209
102	Cellular localization of somatostatin. Metabolism: Clinical and Experimental, 1978, 27, 1151-1159.	3.4	87
103	VIP-, enkephalin-, substance P- and somatostatin-like immunoreactivity in neurons intrinsic to the intestine: immunohistochemical evidence from organotypic tissue cultures. Brain Research, 1978, 155, 239-248.	2.2	194
104	Partial purification and characterization of a muscarinic acetylcholine receptor from rat cerebral cortex. Biochemical and Biophysical Research Communications, 1974, 59, 725-733.	2.1	38